Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in egyptian cancer patients.

cairocure_patient_education (1)

Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in egyptian cancer patients.

Azim HA, Abdal-Kader YS, Mousa MM, Malek RA, Abdalmassih MK, Ibrahim NY.

Asian Pac J Cancer Prev. 2015;16(1):65-9.

Publication Link

← TNMF versus TNM in staging of colorectal cancer Reporting of the circumferential tumour margin involvement and preoperative levels of carcinoembryonic antigen as prognostic risk factors in colorectal cancer patients. →

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

Jun 13, 2023

Khaled H, Azim HA, Barsoum E, Chahine G, Shamseddine A, Metaal GA, Omar A, Jazeih AR, Haggag R, Badran A.

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

New hope on the horizon for patients with metastatic colorectal cancer

Jun 13, 2023

Omar Abdel-Rahman, Hamdy A Azim, Sameh Mikhail, and Mohamed E Salem …

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

Potential Therapeutic Targets in Triple Negative Breast Cancer

Jun 13, 2023

Hamdy A. Azim and Hatem A. Azim Jr. Rep. First online: 23 September 2015. DOI 10.1007/s12609-015-0192-1

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

Pathological features and prognosis of lobular carcinoma in Egyptian breast cancer patients.

Jun 13, 2023

Womens Health (Lond). 2014 Sep;10(5):511-8. doi: 10.2217/whe.14.48.

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

Reporting of the circumferential tumour margin involvement and preoperative levels of carcinoembryonic antigen as prognostic risk factors in colorectal cancer patients.

Jun 13, 2023

Elbarmelgi MY, Farag A, Azim HA, Abozeid AA, Mashour AN, Mikhail HM

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

TNMF versus TNM in staging of colorectal cancer

Jun 13, 2023

Ahmed Farag AF, Elbarmelgi MY, Azim HA, Abozeid AA, Mashhour AN.

« Older Entries